BIOSYMPOSIUM

COVID-19:
A Global Progress Update

NOVEMBER 5, 2020 | half day commencing 8:45 am

Delivered online, details at **www.biomelbourne.org**

MAJOR SPONSOR

CSIRO

SUPPORTING SPONSORS

DAVIES COLLISON CAVE
INTELLECTUAL PROPERTY

SeerPharma®
CONFIDENCE IN COMPLIANCE

Australian Government
Department of Industry, Science, Energy and Resources

AusIndustry
Entrepreneurs' Programme

Welcome

November 5, 2020

2020 – what a year!

It goes without saying that this year has challenged us all and impacted the world in a myriad of different ways. For BioMelbourne Network, it has tested our resilience but also proven our capacity to adapt, and our commitment to supporting our members and industry partners. Through this challenging time the health industry has also shown it's resolve, delivering incredible outcomes with innovative COVID-19 research, fast-tracked vaccine developments and advanced manufacturing collaborations for ventilators, critical PPE and other supplies.

For BioMelbourne Network in particular, the virtual world accompanying COVID-19 has proven a fantastic opportunity to more easily facilitate engagement with those well beyond Melbourne's borders. The switch to an online format allows us to access experts from across Victoria, Australia and the world, all from the comfort of our own home offices. You will likewise be tuning in from your laboratory or hospital ward, the office at your factory or from the same dining room table from which you've been home schooling your children these past months. Our experts will be doing the same.

Our BioSymposium speakers are not only experts in their respective fields - but they are also recognised world leaders. You may recall seeing some of them regularly feature on the nightly news. Others work quietly behind the scenes, securing access to and planning distribution of potential vaccines for COVID-19. This event is an opportunity to showcase their important work. Through them, we will provide insights into global progress with regards to COVID-19 vaccine development, manufacture and distribution, diagnostic testing and therapeutic treatments.

Large events like this are not possible without the support of a number of key players. We extend our gratitude to all of our speakers and facilitators for not only their commitment to this event, but all the work they do supporting our fight against COVID-19. We also extend thanks to the sponsors of our first BioSymposium, including Major Sponsor CSIRO and several Supporting Sponsors. You can read more about our sponsors through this event booklet and on the event website.

At BioMelbourne Network, we'd also like to give a special thanks to our Members, sector colleagues and to all those joining this BioSymposium – it is with your support that we can continue to host informative and valuable events for our sector. We hope that today's speakers inspire you to appreciate the challenges being faced and the work being done, both in Victoria and beyond, to ensure our safety as we work to develop a COVID-normal world.

Jeff Malone
CEO, BioMelbourne Network

Speakers

SESSION 1

JANE HALTON Chair, Coalition for Epidemic Preparedness Innovations (CEPI) and Member, Australia's National COVID-19 Coordination Commission

Jane Halton is a former Secretary of the Australian Department of Finance, responsible for supporting the delivery of the Australian Government Budget, the ongoing management of the Australian Government's non-defence domestic property portfolio, key assets and asset sales, plus the financial and performance framework for Australian Government agencies. She has extensive experience in finance, insurance, risk management, information technology, human resources, health and aging, sport, and public policy, as well as significant international experience.

In a 33-year career within the public service, including nearly 15 years as Secretary, Ms. Halton's previous roles include Secretary of the Australian Department of Health, Secretary for the Department of Health and Ageing, and Executive Co-ordinator (Deputy Secretary) of the Department of the Prime Minister and Cabinet.

Ms. Halton is a member of the Boards of the Australia and New Zealand Banking Group (ANZ Bank), Clayton Utz, and the Australian Strategic Policy Institute. She is also a member of the Board for the Coalition for Epidemic Preparedness Innovations.

Previously, Ms. Halton has held numerous international appointments including the Executive Board of the World Health Organization (2004–2007), President of the World Health Assembly (2007), Chair of the Executive Board of WHO, and Chair of the OECD Health Committee (2007–2012).

Ms. Halton holds the positions of Adjunct Professor at the University of Sydney, and Adjunct Professor at the University of Canberra. She also holds a Doctorate of Letters *honoris causa* from the University of New South Wales.

She was awarded the Public Service Medal in 2002, the Centenary Medal in 2003, and the Geneva Health Prize in 2013. In 2016, Ms. Halton became one of a small number of international members elected to the National Academy of Medicine in the United States.

SESSION 1

PROFESSOR MARY-LOUISE McLAWS Epidemiologist UNSW and Member of the World Health Organization (WHO) Health Emergencies Programme Ad Hoc COVID-19 for Infection Prevention and Control Guidance Development Group

Mary-Louise is an epidemiologist and Member of the World Health Organization (WHO) Health Emergencies Programme Ad Hoc COVID-19 for Infection Prevention and Control Guidance Development Group.

For several years she was a short mission World Health Organization Advisor to China and Malaysia for surveillance development and on the WHO Clean Care is Safer Care Challenge program development and assessment team. She collaborated with Beijing to review the response to the Severe Acute Respiratory Syndrome (SARS) outbreak and healthcare worker safety for the Hong Kong SARS designated hospital. In preparation for pandemic influenza she was commissioned by the Commonwealth to review the Pandemic Influenza Infection Control Guidelines for evidence of protection for healthcare workers.

She has remained an Honorary Advisor to the Clinical Excellence Commission for many years collaborating on several state-wide patient safety interventions including improving hand hygiene in healthcare care workers, reducing central line associated bloodstream infections and detecting and treating sepsis early in patients presenting to emergency departments.

Her research has included the seminal Australian survey of healthcare associated infections (HAI) in 1984 and developed the first standardized surveillance system for HAI as a pilot in 1998–2001 for the NSW Health Department. For the past four years she and a team of UNSW experts are developing wastewater surveillance of antibiotic resistant pathogens. She enjoys capacity building infection control in Cambodia, China, Bangladesh, Mali, Indonesia, Iran, Viet Nam, Taiwan and Turkey.

SESSION 1

BRUCE GOODWIN Managing Director, Janssen Australia and New Zealand & Member of the Board, Medicines Australia

Bruce Goodwin's career with the Johnson & Johnson family of companies spans thirty seven years. He has been in General Management roles for the last eleven years including two terms in his current role of Managing Director Janssen Australia and New Zealand, and also three years as President and Representative Director, Janssen Japan.

Prior to General Management he has held Management Board Director positions in Sales and Marketing and in Finance, as well as having gained valuable experience in Global Licensing and Acquisitions. His service with Johnson & Johnson outside of his home country, Australia, includes postings to Janssen Japan, Janssen Belgium and Janssen United Kingdom.

Bruce is a respected Industry Leader and is currently an elected Director and Board Member of Medicines Australia, a role he has also held previously. Whilst in Japan he served as the Vice Chair of the Japan Based Executive Committee of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Bruce has a strong track record in advocating for policies that support timely and affordable access to innovative medicines and since 2018 has been a Director and Board member of the Australian Genomic Cancer Medicine Centre. In 2017 he was also a key member of the Cancer Drugs Access Committee.

Bruce holds an Economics degree from Macquarie University, an MBA from Macquarie Graduate School of Management, and is a Graduate Member of the Australian Institute of Company Directors (GAICD).

SESSION 1

FACILITATOR: DR ROB GRENFELL Director, Health and Biosecurity Business Unit, CSIRO

Dr Rob Grenfell, a Public Health Physician, is the Director of CSIRO's Health and Biosecurity Business Unit. Leading a broad portfolio covering Nutrition, eHealth, Medtech and Diagnostics and Biosecurity, from weeds to Ebola.

Rob has broad ranging public health experience including; National Medical Director at BUPA Australia New Zealand; National Director Cardiovascular Health at the Heart Foundation; Strategic Health Advisor to Parks Victoria; Senior Medical Advisor at the Department of Health Victoria; Physician in charge of travel health BHP; General Practice.

He was a member of the Safety and Quality Outcomes Committee of the Hospital Innovation Reform Council, a member of the Victorian Quality Council, Chair of General Practice Victoria, and Member of the Health Advisory Committee of the National Health and Medical Research Council.

SESSION 2

DR CAROLINE POPPER Co-Founder and President, Popper and Company

Caroline founded Popper and Company with Ken Walz more than fifteen years ago to address inefficiencies in healthcare by helping life science companies develop and commercialize new technology. Today, the members of their growing team leverage their extensive knowledge of the tools and trends shaping all aspects of healthcare market and impacting its participants.

Caroline has more than 25 years of hands-on operating experience within healthcare companies. She did not set out to be a business person. Rather, she became a physician (University of the Witwatersrand, South Africa) and an internist and pathologist (Johns Hopkins University, Baltimore). Most impactful, was her training in Health Policy and Health Economics at the Johns Hopkins Bloomberg School of Public Health.

Caroline has managed a wide spectrum of diagnostics, device and drug discovery businesses in both Fortune 500 and start-up settings, at amongst others, Becton Dickinson, bioMerieux, and MDS. Now, at her firm, she combines those experiences with her clinical experience to help clients interpret relevant market forces, develop strategies and create partnerships to thrive in the global changing, and increasingly value-driven, healthcare landscape.

Popper and Co. has partnered with Monument Analytics to develop "Precision Econostics," the firms' joint offering designed to optimize therapeutic strategies through the use of advanced diagnostics and digital tools. Precision Econostics, which is in step with Precision Medicine 3.0, utilizes health economic analytic methods and advanced diagnostics expertise to design optimal companion diagnostics strategies for biopharmaceutical clients. The sharp focus on diagnostics and unprecedented interest in diagnostic technologies in 2020 have created lots of interesting and unique and uniquely challenging assignments for Popper and Co.

When Caroline is not trying to "impact the world" she is equally passionate about making an impact at home where her daughter is a college student and her son is an IP lawyer. She grew up in South Africa and has had the opportunity to travel extensively. She loves coffee shops, and modern and tribal art… and she is a cable news junkie. But, in the new normal, like everyone, she has reconfigured work and play to be productive and meaningful in different ways.

SESSION 2

JAIME McCOY General Manager, Gilead Sciences Australia New Zealand



Jaime McCoy was appointed General Manager of Gilead Sciences in Australia and New Zealand in 2019. At Gilead, Jaime oversees all aspects of the Australian business including its liver, HIV and growing haematology oncology business units, as well as steering the company's entry into new therapeutic areas, including emerging viruses such as COVID-19. She led Gilead ANZ's innovative pandemic response, working in close partnership with government and healthcare professionals, to secure registration of the first approved treatment for COVID-19.

Ms McCoy has worked in the pharmaceutical and biotechnology industry for more than 20 years across Asia, Europe and Australia. Starting her career in the pharmaceutical industry as a sales representative, Ms McCoy has enjoyed a meaningful career in a sector she is deeply passionate about, and that aligns with her personal mission of improving the lives of patients and their families.

Before joining Gilead Sciences, Ms McCoy spent five years as the ANZ Managing Director at Japanese pharmaceutical company, Eisai. Under her leadership, the company established a presence in Australia, launching four highly specialised medicines. Prior to Eisai, Jaime has held various senior roles with other pharmaceutical companies, including Takeda, Sanofi and Pfizer.

SESSION 2

ADJUNCT PROFESSOR JOHN SKERRITT Deputy Secretary, Health Products Regulation Group, Australian Department of Health

Adjunct Professor John Skerritt joined the Department of Health in May 2012 and is the Deputy Secretary, Health Products Regulation Group. As a Deputy Secretary, he contributes to the stewardship of Australia's health system, as well as having direct responsibility for both the Therapeutic Goods Administration and the Office of Drug Control.

John is a former Deputy Secretary in the Victorian Government and has extensive experience in medical, agricultural and environmental policy, as well as regulation, research management, technology application and commercialisation. Prior to this role, John was the Deputy CEO of a Commonwealth statutory authority), a Ministerial appointee on the Gene Technology Technical Advisory Committee, and Chair of the Board of an international technical organisation.

During the 1990s he held senior management positions in CSIRO and Cooperative Research Centres. He has significant experience on boards of international and national organisations and has more than 30 years experience in negotiating and leading international technical and commercial collaborations. He is currently Vice-Chair of the International Coalition of Medicines Regulatory Authorities and Chair of the Scientific Advisory Council of the Centre for Innovation in Regulatory Science.

John is an Adjunct Professor of the Universities of Sydney, Queensland and Canberra, has a PhD from the University of Sydney, and is a graduate of the Senior Executive Programs of London Business School and of the International Institute for Management Development (IMD) Business School in Switzerland. He was elected a Fellow of the Academy of Technological Sciences and Engineering and a Fellow of the Institute of Public Administration of Australia (Vic). In 2012, he was the global winner of the Alumni Service Aware from Rotary International for scientific and humanitarian contributions.

SESSION 2

DR FELICIA PRADERA Program Leader – Medical Countermeasures, DMTC Ltd

Felicia Pradera established and leads the National Medical Countermeasures Initiative (MCMi) at DMTC Ltd on behalf of the Defence Science and Technology Group and other government stakeholders. She is responsible for the collaborative development of new platform technology and sovereign industrial capability to support Defence and National Security requirements. Felicia is the co-lead author of the 2012 and 2017 Medical Countermeasures National Capability Audits and is recognized nationally and internationally as the MCM development lead for the country.

Felicia has expertise in academic research (immunology), preclinical and clinical trials, intellectual property and complex program management. She specializes medical countermeasures and health security on behalf of the Government in addition to providing strategic advice and guidance.

Felicia holds a Dr.rer.naturwissenschaftern (PhD) from the Technical University of Berlin, and a Masters of Intellectual Property Law from Monash University.

SESSION 2

FACILITATOR: DR ASHLEY BATES Director, AusIndustry – Entrepreneurs' Programme

Ashley has worked in the Pharmaceutical and Medical Technologies Industry for around 30 years. Starting as a research scientist at The Upjohn Company (now Pfizer) he worked in the UK and USA before moving to Australia with GSK.

Ashley has a deep understanding of the commercialisation of biomedical innovation gained from senior roles in new product development, technology scouting and licencing. In addition to working with multinationals, Ashley also has worked with a variety of SMEs, government-funded initiatives and translational research entities and has served on the boards of NFPs, Cooperative Research Centres and industry associations. In his current role, he has strategic oversight over a number of Federal Government initiatives designed to support growth in the Australian SME sector.

HOST

BioMelbourne Network

BioMelbourne Network
Progressing BioIndustry

Web: www.biomelbourne.org

Twitter: @biomelb

Contact: Vicky Jones
Email: vjones@biomelbourne.org

About Us:

BioMelbourne Network is an industry-led membership association for organisations engaged in biotechnology, medical technology, pharmaceuticals and health innovation in the state of Victoria. Our role is to foster links between companies, research organisations, financial markets and government, creating an environment for greater collaboration and prosperity.

With around 180 member organisations, BioMelbourne Network plays a critical role in connecting health, research and industry capabilities and supporting the growth of Melbourne's innovation economy. BioMelbourne Network's focus is local and our reach is global. The ultimate success of our members is built on a strong foundation of research and development, and a globally competitive innovation ecosystem here in Victoria.

MAJOR SPONSOR

CSIRO

Web: www.csiro.au/en/Contact

Call: 1300 363 400

About Us:

As Australia's national science agency and innovation catalyst, CSIRO solves the greatest challenges through innovative science and technology.

We work with organisations large and small, delivering world-leading research and development solutions to help their business innovate, improve and grow.

With 5,000 experts, state-of-the-art facilities, and a global collaborative research network we bring together the best and brightest minds to drive strategic growth and overcome unique business challenges like no other.

Driven to create and facilitate societal, environmental and economic impact, we work with organisations across all major sectors and at all stages of the innovation lifecycle from strategic advice and planning, research and development, through to commercialisation and funding.

CSIRO. Unlocking a better future for everyone.

SUPPORTING SPONSORS

Department of Industry, Science, Energy and Resources

Australian Government
Department of Industry, Science, Energy and Resources

AusIndustry
Entrepreneurs' Programme

Web: www.business.gov.au/EP

Call: 13 28 46

About Us:

The Entrepreneurs' Programme delivers advice and grants to enable high-potential businesses to strengthen, grow, innovate and commercialise nationally and globally. The program offers a variety of services to support Australian businesses:

Growth Services: improve your capability to trade and export in global markets.

Strengthening Business: get your business back on track after the 2019-20 Black Summer bushfires.

Accelerating Commercialisation: take your novel product, process or service into production and get it to market.

Innovation Connections: connect with the research sector and undertake projects to develop innovative solutions.

Incubator Support Initiative: receive funding for incubators that support Australian start-ups with an international focus.

SUPPORTING SPONSORS

SeerPharma

SeerPharma®
CONFIDENCE IN COMPLIANCE

Web: www.seerpharma.com

Contact: Biju Kishor
Email: biju.kishor@seerpharma.com.au

About Us:

SeerPharma is a team of consultants that provide advice, training, software and contract labour resources to pharmaceutical, medical device and life science companies in the Asia-Pacific region on matters of Quality Assurance and GMP compliance. We have been serving our clients in the Asia-Pacific region for over 30 years from our offices in Melbourne, Sydney and Singapore and are also able to provide assistance in Europe through our affiliate in the UK.

Our team of consultants have extensive experience working with clients supplying, or looking to enter the supply chain of a therapeutic product. We work with organisations looking to ensure that their facilities, equipment, quality systems and processes are compliant with FDA, PIC/S, TGA, WHO, ISO, ICH and other regulations and standards that apply to their product(s). Our consultants actively train and provide advice to companies on matters of compliance from Research and Development through to Manufacturing, Logistics, Warehousing and Post Market Surveillance. We regularly inspect organisations on behalf of the Australian Government (APVMA) as well as Pharmaceutical and Medical Device organisations relying on suppliers in the Asia-Pacific region. Our IT Solutions team routinely implement electronic Quality Management Systems to help improve process efficiencies within organisations. Companies also turn to SeerPharma to provide short term Quality Assurance contractors to help with projects that do not warrant hiring a full or part time employee.

Through our work we aim to "Advance Quality and GMP Best Practices in the APAC region" for the Pharmaceutical and Medical Device Industry.

SUPPORTING SPONSORS

Davies Collison Cave

DAVIES
COLLISON
CAVE
INTELLECTUAL PROPERTY

Web: www.dcc.com

Contact: Dr Alex Tzanidis
Email: atzanidis@davies.com.au

About Us:

Davies Collison Cave is one of Australia's largest intellectual property (IP) firms. We provide patent, trade mark, design and copyright, commercialisation, privacy and data protection services in Australia, New Zealand, Singapore and the ASEAN region and are committed to understanding your IP in the context of your business. We are focused on providing excellent service and leadership within the IP profession.

Our attorneys and lawyers are among the most qualified and experienced IP specialists in the country, with broad science and technology backgrounds that allow them to understand and protect your innovation.

To find out more please visit dcc.com

MAJOR SPONSOR

CSIRO

SUPPORTING SPONSORS

SeerPharma®
CONFIDENCE IN COMPLIANCE

DAVIES COLLISON CAVE
INTELLECTUAL PROPERTY

Australian Government
Department of Industry, Science, Energy and Resources

AusIndustry
Entrepreneurs' Programme

BioMelbourne Network
Progressing BioIndustry

BioMelbourne Network

ANZAC House
4 Collins Street
Melbourne, Australia 3000

T: 03 9667 8181
E: info@biomelbourne.org
www.biomelbourne.org
#BioSymposium